Tratamento UCon de bexiga hiperativa (OAB) em homens
Segurança e desempenho de UCon para gerenciamento de OAB não neurogênico em homens - um estudo de viabilidade inicial
UCon is a medical device for treatment of the symptoms of OAB and fecal incontinence (FI). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder musculature e.g., suppress undesired bladder activity to relieve the symptoms of the patient. This clinical investigation is a randomized, cross-over, single-site, prospective, early feasibility study, which is used to evaluate Ucon with respect to its initial clinical safety and device performance in a small number of males with OAB.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
The purpose of the current investigation is to obtain information about the type of stimulation that Ucon provide (time limited vs. urge stimulation), would be the most effective and feasible for the treatment of non-neurogenic OAB symptoms in males.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Dianna Mærsk Knudsen
- Número de telefone: +45 40517712
- E-mail: dmk@innoconmedical.dk
Locais de estudo
-
-
-
Maastricht, Holanda
- Recrutamento
- Maastricht University Medical Center+
-
Contato:
- John Heesakkers, MD
- Número de telefone: +31 433877258
- E-mail: john.heesakkers@mumc.nl
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Subject is ≥ 18 years of age.
- Subject is male.
- Subject is diagnosed with OAB
- Subject is able to communicate, provide feedback, understand and follow instructions during the course of the investigation.
Exclusion Criteria:
-
Subject is medically unstable (acute illness or complications of a chronic condition that might affect the subject's participation in the investigation).
-
Subject has a Post Void Residual (PVR) of more than 100 ml or a Bladder Voiding Efficiency (BVE) of less than 75% (measured by uroflowmetry as the ratio of voided volume (VV) and total bladder capacity (VV+PVR)).
-
Subject has an active infection in the genital area incl. skin infections and urinary tract infection.
-
Subject has had botulinum toxin (BOTOX) treatment in the pelvic region within 6 months.
-
Subject has used antimuscarinics or β3 agonists within 14 days weeks*.
-
Subject has an implanted pacemaker, implantable drug pump or other active medical device (any medical device that uses electrical energy or other source of power to make it function).
-
Subject is enrolled or planning to enrol in another clinical investigation or was enrolled in an investigational drug study or medical device investigation within four weeks to enrolment.
-
Subject has neuropathy to a degree that is presumed to diminish the effect of the electrical stimulation.
-
Subject has a history of cancer in the pelvic region, are currently receiving cancer treatment, or has radiation-induced damage to the pelvic region.
-
Subject has addictive behaviour defined as abuse of alcohol, cannabis, opioids, or other intoxicating drugs.
-
Subject does not speak and understand Dutch.
- If a subject is currently being treated with antimuscarinics or β3 agonists, he is allowed to be included in the investigation, however, a washout period of 14 days is required before baseline can be established.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Outro: Group A (Urge and Time limited)
The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) using UCon with a stimulation mode that is activated for 60 seconds by the participant when he experience urgency (urge stimulation).The urge stimulation can be activated repeatedly during the day as the participant wears the device from morning to evening at home for 14 days. Following a stimulation wash-out period (14 days), the participants then stimulates with UCon for another 14 days using the time limited stimulation mode. |
Participants will receive stimulation for 60 seconds, when they feel an urgency.
Outros nomes:
Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.
Outros nomes:
|
|
Outro: Group B (Time limited and Urge)
The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) using UCon with a stimulation mode that is activated for 30 minutes once a day, at a time that is convenient for the participant. The participant uses the device at home for 14 days. Following a stimulation wash-out period (14 days), the participant then stimulates with UCon for another 14 days using the urge stimulation mode. |
Participants will receive stimulation for 60 seconds, when they feel an urgency.
Outros nomes:
Participant will receive the stimulation as provided in time limited sessions (Range: 15 min - continuous), whenever it suits the participant during the day.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
PRIMARY SAFETY: To evaluate adverse events [initial safety] of UCon for treatment of OAB symptoms in a home setting.
Prazo: After 44 days (end of study)
|
Characterization of adverse events and anticipated adverse device effects associated with the use of UCon during the investigational period. |
After 44 days (end of study)
|
|
PRIMARY PERFORMANCE: To evaluate the ratio of treatment change [performance] of OAB symptoms using UCon in a home setting
Prazo: Change from baseline at 14 days, 30 days and 44 days (study end)
|
Ratio of subjects with at least 50% change in their OAB symptoms from baseline. Participants shall complete a 3-day bladder diary to report their symptoms. The symptoms related to OAB:
|
Change from baseline at 14 days, 30 days and 44 days (study end)
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
SECONDARY SAFETY: To identify the number of subjects experiencing adverse events associated with the use of UCon during the investigational period.
Prazo: After 44 days (end of study)
|
Number of subjects experiencing adverse events and anticipated adverse device effects. Subjects will report on any experience associated with the use of UCon. |
After 44 days (end of study)
|
|
SECONDARY SAFETY: To evaluate the severity of adverse events associated with the use of UCon during the investigational period.
Prazo: After 44 days (study end)
|
Severity of adverse events and anticipated adverse device effects.The severity will be evaluated from the subjects' report on any experience associated with the use of UCon. |
After 44 days (study end)
|
|
SECONDARY PERFORMANCE: To evaluate whether subjects using UCon experience a change in their quality of life.
Prazo: Change from baseline at 14 days and 44 days (end of study)
|
Ratio of subjects with a change in their OAB quality of life measures as assessed by specific QoL questionnaires related to OAB condition (ICIQ-OAB, AOBq). An overall score with greater values indicates a worse symptom outcome. |
Change from baseline at 14 days and 44 days (end of study)
|
|
SECONDARY PERFORMANCE: To evaluate whether subjects using UCon experience a change in their treatment outcome (i.e. symptoms) after therapy.
Prazo: Change from baseline at 14 days and 44 days (end of study)
|
Ratio of subjects with a change in their treatment outcome (i.e. symptoms) assessed by the 7-point Patient Global Impression of Improvement (PGI-I) scale. Higher scores indicates a worse treatment outcome. |
Change from baseline at 14 days and 44 days (end of study)
|
|
SECONDARY PERFORMANCE: To evaluate the device and treatment acceptability of UCon.
Prazo: After 44 days (study end)
|
Ratio of subjects that accept UCon and DGN stimulation as assessed by a satisfaction survey recorded after each stimulation period. |
After 44 days (study end)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: John Heesakkers, MD, Maastricht UMC+, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Transtornos Mentais, Desordem Mental
- Doenças Urogenitais Masculinas
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Distúrbios da micção
- Sintomas do Trato Urinário Inferior
- Manifestações Urológicas
- Sintomas Comportamentais
- Distúrbios de Eliminação
- Condições Patológicas, Sinais e Sintomas
- Comportamento
- Sinais e sintomas
- Enurese
- Incontinencia urinaria
- Enurese Noturna
- Incontinência Urinária, Urgência
- Noctúria
Outros números de identificação do estudo
Outros números de identificação do estudo
- NL_FEAS_01
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .